Sex Differences in Endovascular Treatment for Stroke: A Population-based Analysis.


Journal

The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques
ISSN: 0317-1671
Titre abrégé: Can J Neurol Sci
Pays: England
ID NLM: 0415227

Informations de publication

Date de publication:
07 2021
Historique:
pubmed: 22 10 2020
medline: 30 9 2021
entrez: 21 10 2020
Statut: ppublish

Résumé

Acute ischemic stroke may affect women and men differently. We aimed to evaluate sex differences in outcomes of endovascular treatment (EVT) for ischemic stroke due to large vessel occlusion in a population-based study in Alberta, Canada. Over a 3-year period (April 2015-March 2018), 576 patients fit the inclusion criteria of our study and constituted the EVT group of our analysis. The medical treatment group of the ESCAPE trial had 150 patients. Thus, our total sample size was 726. We captured outcomes in clinical routine using administrative data and a linked database methodology. The primary outcome of our study was home-time. Home-time refers to the number of days that the patient was back at their premorbid living situation without an increase in the level of care within 90 days of the index stroke event. In adjusted analysis, EVT was associated with an increase of 90-day home-time by an average of 6.08 (95% CI -2.74-14.89, p-value 0.177) days in women compared to an average of 11.20 (95% CI 1.94-20.46, p-value 0.018) days in men. Further analysis revealed that the association between EVT and 90-day home-time in women was confounded by age and onset-to-treatment time. We found a nonsignificant nominal reduction of 90-day home-time gain for women compared to men in this province-wide population-based study of EVT for large vessel occlusion, which was only partially explained by confounding.

Sections du résumé

BACKGROUND
Acute ischemic stroke may affect women and men differently. We aimed to evaluate sex differences in outcomes of endovascular treatment (EVT) for ischemic stroke due to large vessel occlusion in a population-based study in Alberta, Canada.
METHODS AND RESULTS
Over a 3-year period (April 2015-March 2018), 576 patients fit the inclusion criteria of our study and constituted the EVT group of our analysis. The medical treatment group of the ESCAPE trial had 150 patients. Thus, our total sample size was 726. We captured outcomes in clinical routine using administrative data and a linked database methodology. The primary outcome of our study was home-time. Home-time refers to the number of days that the patient was back at their premorbid living situation without an increase in the level of care within 90 days of the index stroke event. In adjusted analysis, EVT was associated with an increase of 90-day home-time by an average of 6.08 (95% CI -2.74-14.89, p-value 0.177) days in women compared to an average of 11.20 (95% CI 1.94-20.46, p-value 0.018) days in men. Further analysis revealed that the association between EVT and 90-day home-time in women was confounded by age and onset-to-treatment time.
CONCLUSIONS
We found a nonsignificant nominal reduction of 90-day home-time gain for women compared to men in this province-wide population-based study of EVT for large vessel occlusion, which was only partially explained by confounding.

Identifiants

pubmed: 33081850
pii: S0317167120002371
doi: 10.1017/cjn.2020.237
doi:

Types de publication

Journal Article Multicenter Study Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

479-486

Auteurs

Charlotte Zerna (C)

Department of Clinical Neurosciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
Department of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.

Edwin Rogers (E)

Clinical Analytics, Alberta Health Services, Edmonton, Alberta, Canada.

Doreen M Rabi (DM)

Department of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.

Andrew M Demchuk (AM)

Department of Clinical Neurosciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada.
Department of Radiology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.

Noreen Kamal (N)

Department of Industrial Engineering, Dalhousie University, Halifax, Nova Scotia, Canada.

Balraj Mann (B)

Cardiovascular Health and Stroke Strategic Clinical Network, Alberta Health Services, Edmonton, Alberta, Canada.

Tom Jeerakathil (T)

Division of Neurology, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.

Brian Buck (B)

Division of Neurology, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.

Ashfaq Shuaib (A)

Division of Neurology, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.

Jeremy Rempel (J)

Department of Radiology and Diagnostic Imaging, University of Alberta, Edmonton, Alberta, Canada.

Bijoy K Menon (BK)

Department of Clinical Neurosciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada.

Mayank Goyal (M)

Department of Clinical Neurosciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
Department of Radiology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.

Michael D Hill (MD)

Department of Clinical Neurosciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
Department of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada.
Department of Radiology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH